Treatment with programmed cell death 1 (PD‐1) and programmed cell death ligand 1 (PD‐L1) inhibitors has become a key part of the therapeutic strategy for patients with advanced non‐small‐cell lung cancer (NSCLC).1, 2, 3, 4. This evidence concerns the gene CD274 and non-small cell lung carcinoma.